Targeted approaches to treat autoimmune diseases would improve upon current therapies
that broadly suppress the immune system and lead to detrimental side effects. Antigen …

The development of nanomaterials to induce antigen-specific immune tolerance has shown
promise for treating autoimmune diseases. While PEGylation has been widely used to …

Current strategies for treating autoimmunity involve the administration of broad-acting
immunosuppressive agents that impair healthy immunity. Intravenous (iv) administration of …

Targeted immune tolerance is a coveted therapy for the treatment of a variety of autoimmune
diseases, as current treatment options often involve nonspecific immunosuppression …

Tolerogenic nanoparticles (NPs) are rapidly being developed as specific immunotherapies
to treat autoimmune disease. However, many NP-based therapies conjugate antigen (Ag) …

Polymeric nanoparticles (NPs) have demonstrated their potential to induce antigen (Ag)-
specific immunological tolerance in multiple immune models and are at various stages of …

Allogeneic cell therapies have either proven effective or have great potential in numerous
applications, though the required systemic, life-long immunosuppression presents …

Immune‐mediated hypersensitivities such as autoimmunity, allergy, and allogeneic graft
rejection are treated with therapeutics that suppress the immune system, and the lack of …

Current treatments to control pathological or unwanted immune responses often use broadly
immunosuppressive drugs. New approaches to induce antigen-specific immunological …

The type of immune response developed against the hepatitis B virus (HBV) is crucial in
determining the outcome of the disease. The protective effects of vaccine‐induced antibody …